<DOC>
	<DOCNO>NCT00992186</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness study drug carlumab participant metastatic castrate-resistant prostate cancer ( cancer gland make fluid aid movement sperm ) .</brief_summary>
	<brief_title>A Study Safety Efficacy Single-agent Carlumab ( Anti-Chemokine Ligand 2 CCL2 ) Participants With Metastatic Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter trial ( conduct one center ) participant metastatic castrate-resistant prostate cancer . The trial consist 3 phase : screening period , treatment period approximately 4 month , follow-up period ( Week 1 , 4 , 8 12 last dose ) 12 week administration last dose . The participant receive carlumab dose 15 milligram/kilogram ( mg/kg ) intravenous ( vein ) infusion ( fluid medicine deliver vein way needle ) constant rate 90 minute period every 2 week disease progression . Efficacy participant primarily evaluate composite response . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histological documentation adenocarcinoma prostate Received least 1 2 prior docetaxelbased chemotherapy regimens disease progression follow last therapy Serum prostate specific antigen ( PSA ) great equal 5.0 nanogram/milliliter ( ng/ml ) within 4 week prior first dose study agent Orchiectomy ( surgery remove one testicle ) testosterone less 50 nanogram/deciliter mean pharmacological/chemical castration within 4 week prior first dose study agent At least 6 week prior docetaxel chemotherapy regimen first dose study agent Experience hormonal treatment withdrawal response ( include lower PSA previously rise symptomatic improvement ) Known symptomatic Central Nervous System metastases Residual toxicity result previous therapy Grade 2 ( except alopecia ) Known allergy , hypersensitivity , intolerance carlumab excipients clinically significant reaction chimeric human protein Vaccinated live , attenuated vaccine within 4 week prior first dose study agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Infusion</keyword>
	<keyword>Carlumab</keyword>
	<keyword>CNTO 888</keyword>
</DOC>